HER2 therapy: Molecular mechanisms of trastuzumab resistance

@article{Nahta2006HER2TM,
  title={HER2 therapy: Molecular mechanisms of trastuzumab resistance},
  author={Rita Nahta and Francisco J. Esteva},
  journal={Breast Cancer Research},
  year={2006},
  volume={8},
  pages={215 - 215}
}
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within one year of treatment initiation, and in the adjuvant setting 15% of patients still relapse despite trastuzumab-based therapy. In this review, we discuss potential mechanisms of antitumor activity by trastuzumab, and how these mechanisms become altered to promote therapeutic resistance. We… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
177 Citations
71 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 177 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 71 references

Similar Papers

Loading similar papers…